Clinical Surgical Oncology最新文献

{"title":"Intravenous albumin in surgical oncology patients: A systematic review and meta-analysis","authors":"Aviva Moses ,&nbsp;Bram Rochwerg ,&nbsp;Sasha Kyser-Burke ,&nbsp;Katherine Zhu ,&nbsp;Abdullah Bhuiyan ,&nbsp;Samantha J. McCluskey ,&nbsp;Omar I. Hajjaj ,&nbsp;Shangari Vijenthira ,&nbsp;Justyna Bartoszko ,&nbsp;Stuart A. Mc Cluskey ,&nbsp;Edward G. Clark ,&nbsp;Angela Jerath ,&nbsp;Natalie Coburn ,&nbsp;Julie Hallet ,&nbsp;Christopher J.D. Wallis ,&nbsp;Sunil Patel ,&nbsp;Andrew Giles ,&nbsp;Jacqueline Trudeau ,&nbsp;Alexander Dotto ,&nbsp;Sarah McIsaac ,&nbsp;Wiley Chung","doi":"10.1016/j.cson.2026.100135","DOIUrl":"10.1016/j.cson.2026.100135","url":null,"abstract":"<div><h3>Background</h3><div>Intravenous albumin is commonly administered during surgical oncology procedures despite limited evidence of benefit. This systematic review and meta-analysis evaluated whether albumin administration, compared to alternative fluid strategies, improves outcomes in patients undergoing cancer surgery.</div></div><div><h3>Methods</h3><div>We searched MEDLINE, EMBASE, and Cochrane databases from inception to March 5, 2025, without language restrictions, following PRISMA and Cochrane guidelines. We included randomized controlled trials (RCTs) comparing albumin with alternative fluid strategies (crystalloids, synthetic colloids, or no albumin) in adult cancer surgery patients. We evaluated outcomes rated as important or critical by an expert panel, performed meta-analyses using random-effects models, and assessed certainty of evidence using GRADE.</div></div><div><h3>Results</h3><div>We included nine RCTs (n = 890 patients), five of which used crystalloids as the comparator. Pooled analysis found there may be no difference between albumin and alternative fluid groups in total complication rates (risk ratio [RR] = 0.96; 95% confidence interval [CI]: 0.68 to 1.35), intensive care unit or hospital length of stay, or perioperative blood loss (all low to moderate certainty). Effects on mortality and inotrope/vasopressor use were uncertain (very low certainty). Albumin administration was probably associated with a lower perioperative fluid balance (mean difference [MD] = −169.97 mL; 95% CI: −293.41 to −46.52, moderate certainty).</div></div><div><h3>Conclusions</h3><div>Current evidence suggests albumin may not improve patient-important outcomes in surgical oncology. The modest reduction in fluid balance observed with albumin is unlikely to be clinically meaningful, and routine albumin use may contribute to unnecessary healthcare costs. Larger, multicentre RCTs are needed to guide evidence-based perioperative fluid management in surgical oncology.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"5 2","pages":"Article 100135"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148184795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surgical interventions improve survival in patients with metastatic uveal melanoma","authors":"Jacob Fingret ,&nbsp;Karen Sisley ,&nbsp;Manoj K. Valluru ,&nbsp;Ian Rennie ,&nbsp;Sachin M. Salvi ,&nbsp;Heather Allen ,&nbsp;Ali Majeed","doi":"10.1016/j.cson.2025.100102","DOIUrl":"10.1016/j.cson.2025.100102","url":null,"abstract":"<div><h3>Background</h3><div>Metastatic uveal melanoma (UM) has a poor prognosis. UM predominately metastasizes to the liver. Surgical treatment of liver metastasis from uveal melanoma (LMUM) remains controversial. We evaluated the survival of LMUM patients treated with different primary (enucleation, proton beam, Ruthenium plaque, stereotactic radiosurgery and metastatic surgical interventions (resection ± radiofrequency ablation – RFA) compared with chemotherapy alone or no treatment.</div></div><div><h3>Methods</h3><div>100 LMUM patients were studied. 33 had surgical interventions, 46 had chemotherapy alone and 21 had no treatment. Mean survival time was analysed for each primary and metastatic treatment group. The overall difference in survival times from primary diagnosis and metastatic diagnosis was analysed using chi-squared and log rank tests.</div></div><div><h3>Results</h3><div>Mean survival times (months) since metastatic diagnosis for the surgery group (40.088) and RFA + surgery group (34.010) were significantly longer than the chemotherapy group (21.631) and the no treatment group (8.325); <em>p&lt;0.001.</em> Time interval differences between primary and metastatic diagnoses were not significant between secondary metastatic treatment groups but were significant between primary treatment groups (<em>p=0.003)</em>: multiple primary treatments and ruthenium plaque had the longest intervals.</div></div><div><h3>Conclusion</h3><div>This retrospective study highlights how survival can be improved by surgical management of LMUM patients in selected cases.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"5 2","pages":"Article 100102"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148241759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is surgical resection justified in colorectal liver metastasis with synchronous metastasis in lymph nodes of hepatoduodenal ligament (group 12)","authors":"Veronika Patsko ,&nbsp;Illia Pepenin ,&nbsp;Vitaliy Poylin ,&nbsp;Andrii Lukashenko ,&nbsp;Oleksandr Kvasivka ,&nbsp;Kostiantyn Kopchak","doi":"10.1016/j.cson.2026.100132","DOIUrl":"10.1016/j.cson.2026.100132","url":null,"abstract":"<div><div>Colorectal cancer (CRC) is one of the most common malignancies worldwide. Most CRC metastases are found in the liver. Although metastasectomy of liver metastases might be curative, the role of hepatic lymph node dissection remains unclear. The purpose of this study is to understand the effect of portal lymph node dissection in addition to metastasectomy on long-term outcomes.</div><div>Overall, 2353 patients with liver metastasis were identified during the study period. Among them, 38 patients with positive lymph nodes were identified. 28.9% (n = 11) of lymph nodes were found to be positive on final pathologic examination. Average follow-up was 24.2 (0.1–60.9) months. Median progression-free survival for patients with proven positive lymph nodes was 7 months, and 26 months in patients with negative lymph nodes (95% CI of ratio 0.03872 to 0.5772, p = 0.5108, HR = 1.568), which was not statistically significant. Median overall survival was 28.5 (0.1-61). Patients with positive portal lymph nodes had a median overall survival of 9 months, compared with those with negative lymph nodes, but this difference was not statistically significant.</div><div>We found that resection of lymph nodes of the 8th and 12th groups does not worsen surgical outcomes, but it also does not improve oncological outcomes.</div><div>Overall, surgical treatment of liver metastases should be considered as a part of treatment intent for patients with metastatic colorectal cancer, but the presence of enlarged lymph nodes of the hepato-duodenal ligament should be assessed as a negative prognostic factor; this risk has to be taken into consideration. Further studies are required to assess whether this method is better compared to systemic therapy.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"5 2","pages":"Article 100132"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148184796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET-CT in initially resectable pancreatic cancer: Does it change the management?","authors":"Tareq Al Saoudi,&nbsp;Kanika Chawla,&nbsp;Dawud Sarwar,&nbsp;John Isherwood,&nbsp;Neil Bhardwaj,&nbsp;Ashley Dennison,&nbsp;Giuseppe Garcea","doi":"10.1016/j.cson.2026.100131","DOIUrl":"10.1016/j.cson.2026.100131","url":null,"abstract":"<div><h3>Introduction</h3><div>Pancreatic ductal adenocarcinoma (PDAC) remains a major global health challenge. While multidetector CT (MDCT) is the standard imaging modality for staging, the additional value of PET-CT in potentially resectable disease remains uncertain.</div></div><div><h3>Methods</h3><div>We conducted a six-year retrospective study of patients who underwent PET-CT for suspected PDAC. Demographics, cross-sectional imaging findings, PET-CT results, multidisciplinary team (MDT) decisions, operative outcomes, and histology were analysed. Rates of surgery with curative intent and time intervals between imaging and intervention were recorded.</div></div><div><h3>Results</h3><div>Among 161 patients, 110 were considered operable with curative intent, while 51 were deemed unsuitable for surgery. Of the operable group, 20 demonstrated extra-pancreatic PET-avid lesions and 90 did not. In patients without extra-pancreatic uptake, 68 underwent surgical exploration; 48 achieved successful resection and 20 were found to have unresectable disease. In 9 patients, suspected metastases on prior imaging were not confirmed on PET-CT. Among the 20 patients with extra-pancreatic lesions, PET-CT identified unequivocal metastases in 4, precluding surgery. The remaining 16 underwent exploration following MDT review; 9 were resectable and 7 were unresectable. Overall, PET-CT altered management in 8% of cases. The median interval between MDCT and PET-CT was 27 days, and between MDT discussion and PET/CT was 12.5 days.</div></div><div><h3>Conclusion</h3><div>PET-CT influences management in a minority of patients with potentially resectable PDAC, However, routine use may not be justified. Prospective studies are required to define clear selection criteria, and emerging artificial intelligence–based risk stratification tools may support more targeted and efficient utilisation in future practice.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"5 2","pages":"Article 100131"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148241758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inferior mesenteric artery no. 253 lymph node dissection with preservation of the left colic artery: Controversies revisited","authors":"Jingtao Huang ,&nbsp;Enhao Wei ,&nbsp;Mingming Xie ,&nbsp;Siyi Wu ,&nbsp;Yangming Li ,&nbsp;Xinyu Li ,&nbsp;Chunkang Yang ,&nbsp;Shen Guan","doi":"10.1016/j.cson.2026.100130","DOIUrl":"10.1016/j.cson.2026.100130","url":null,"abstract":"<div><h3>Background</h3><div>In radical resection for rectal cancer, the optimal dissection strategy for lymph nodes at the root of the inferior mesenteric artery (IMA, No. 253) remains a subject of intense debate. Traditional high ligation (HGL) facilitates comprehensive lymphatic clearance but risks compromising anastomotic blood supply and injuring pelvic autonomic nerves. While low ligation (LGL) with preservation of the left colic artery (LCA) aims to balance oncological radicality with functional preservation, its long-term safety and specific indications require further clarification.</div></div><div><h3>Methods</h3><div>This review systematically evaluates international paradigm shifts, recent anatomical insights, and existing evidence-based medical data regarding No. 253 lymph node dissection (LND). We analyzed the trade-offs between HGL and LGL-LCA techniques in terms of oncological outcomes, anastomotic complications, and postoperative quality of life.</div></div><div><h3>Results</h3><div>Current evidence suggests that LCA preservation may reduce the incidence of anastomotic leakage and defecatory dysfunction without compromising short-term oncological safety. However, the technical complexity and anatomical variations of the IMA region pose challenges for standardization. Based on this reappraisal, we propose a \"Modular Zonal Dissection Strategy.\" This approach categorizes the IMA root into specific surgical zones, allowing for a structured and reproducible workflow that prioritizes both anatomical precision and surgical safety.</div></div><div><h3>Conclusion</h3><div>The proposed modular zonal dissection strategy provides a standardized framework for No. 253 LND with LCA preservation. By simplifying the surgical workflow and enhancing anatomical clarity, this strategy aims to achieve an optimal balance between radical oncological clearance and the protection of postoperative function in rectal cancer patients.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"5 2","pages":"Article 100130"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148184797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type B1 rotationplasty using patient-specific jigs and navigation for post-oncologic femoral osteomyelitis","authors":"G.G.J. Krebbekx ,&nbsp;A.M.F. Vennik ,&nbsp;L.E. Bröerken ,&nbsp;M. Baas ,&nbsp;D.T. Meijer ,&nbsp;F.G.M. Verspoor","doi":"10.1016/j.cson.2026.100134","DOIUrl":"10.1016/j.cson.2026.100134","url":null,"abstract":"<div><div>We report a Winkelmann Type B1 rotationplasty in a 40-year-old woman with chronic femoral osteomyelitis, extensive soft tissue loss, and vascular compromise following sarcoma resection, chemotherapy, and radiotherapy. Conventional limb salvage was no longer feasible. A multidisciplinary approach using patient-specific cutting guides and intraoperative navigation enabled precise osteotomies, optimal alignment, and stable fixation. This strategy may have improved surgical accuracy and bone contact. Rotationplasty may provide an alternative to hip disarticulation in a complex post-oncologic case.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"5 2","pages":"Article 100134"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148241757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indocyanine green fluorescence for the intraoperative detection of extrahepatic hepatocellular carcinoma: a systematic review and pooled-analysis","authors":"Emanuele Mini ,&nbsp;Davide Citterio ,&nbsp;Marianna Maspero ,&nbsp;Isabella Pezzoli ,&nbsp;Carlo Sposito ,&nbsp;Vincenzo Mazzaferro","doi":"10.1016/j.cson.2026.100133","DOIUrl":"10.1016/j.cson.2026.100133","url":null,"abstract":"<div><div>Indocyanine green (ICG) is exclusively uptaken by hepatocytes and rapidly cleared. Hepatocellular carcinoma (HCC) cells may also uptake ICG, but their clearance may be impaired, thus remaining fluorescent for a prolonged period of time. This characteristic may be exploited to visualize not only intrahepatic HCCs, but also extrahepatic HCC implants. We conducted a systematic literature search on Medline, Scopus, Web of Science (WoS) Core Collection and the Cochrane library to identify studies on the use of ICG fluorescence for the intraoperative visualization of extrahepatic HCC until December 2024. Eleven studies were included for a total of 44 patients: seven studies were case reports, two studies were small case series (2 patients), and two studies were larger case series (≥15 patients). The studies reported a total of 119 lesions suspected of extrahepatic localization of HCC with an ICG-detection rate after intravenous ICG infusion of 89.0%; 22 new lesions positive for ICG fluorescence not suspected during pre-operatory planning were identified intraoperatively. Among all removed fluorescent lesions, only 4 were negative for HCC. Sensitivity was 91.9%, specificity 33.3% (based on only 6 HCC-negative lesions), accuracy 89.4% while the positive predictive value 96.9%. Per-site diagnostic accuracy varied substantially, as sensitivity was 89.2% for the lungs, 93.8% for lymph nodes and 100% for peritoneum. Overall, the use of ICG as a guiding tool for intraoperative identification and dissection of extrahepatic localization of HCC appears promising, although further evidence is needed to assess whether ICG can become a standard of care in this setting.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"5 2","pages":"Article 100133"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148184798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathologic complete response and durable progression-free survival following neoadjuvant chemo-immunotherapy and surgery for stage IIIB small cell lung cancer: A case report","authors":"Lingye Zeng ,&nbsp;Taiguo Liu ,&nbsp;Ping Zhou ,&nbsp;Qinghua Zhou ,&nbsp;Yan Zhang","doi":"10.1016/j.cson.2026.100123","DOIUrl":"10.1016/j.cson.2026.100123","url":null,"abstract":"<div><div>Small cell lung cancer (SCLC) is an aggressive malignant tumor characterized by early dissemination and an extremely poor prognosis. The current standard-of-care treatment for limited-stage SCLC (LS-SCLC) is concurrent chemoradiotherapy followed by Durvalumab based on the phase III ADRIATIC trial. However, further research on patterns of disease progression has revealed that intrathoracic lesions were more likely to occur than extrathoracic lesions as the first site of progression, which indicates even though SCLC is considered a systemic disease, better local control measures are still needed for LS-SCLC. Neoadjuvant chemo-immunotherapy and surgery are becoming the standard treatment for resectable non-small cell lung cancer (NSCLC). It remains unclear whether the combination of immunotherapy and chemotherapy is beneficial for SCLC in the neoadjuvant setting. Here, we report a case of a patient with stage IIIB SCLC who underwent surgery and has remained disease-free for 21 months after three cycles of neoadjuvant chemo-immunotherapy, aiming to provide an illustrative basis for this treatment modality.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"5 1","pages":"Article 100123"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147397240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging advances in integrating minimally invasive surgery into the therapeutic landscape of locally advanced non-small cell lung cancer","authors":"Wei Yin ,&nbsp;Peiling Chen ,&nbsp;Tianrui He ,&nbsp;Weisheng Guo ,&nbsp;Wen Zhong ,&nbsp;Shengbao Suo ,&nbsp;Shuben Li ,&nbsp;Wenhua Liang ,&nbsp;Jianxing He ,&nbsp;Yao Guo ,&nbsp;René Horsleben Petersen ,&nbsp;Gaetano Rocco ,&nbsp;Alessandro Brunelli ,&nbsp;Calvin S.H. Ng ,&nbsp;Thomas A. D'Amico","doi":"10.1016/j.cson.2025.100115","DOIUrl":"10.1016/j.cson.2025.100115","url":null,"abstract":"<div><div>Locally advanced non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer-specific mortality, yet the therapeutic value of surgery remains contentious. However, driven by the success of recent neoadjuvant clinical trials, the treatment landscape for locally advanced NSCLC has evolved dramatically, significantly influencing patient-reported and oncological outcomes. Consequently, the strategic integration of surgery, particularly minimally invasive surgery (MIS) such as video-assisted thoracoscopic surgery (VATS) and robotic-assisted thoracic surgery (RATS), into the management of highly selected post-neoadjuvant patients is associated with improved long-term survival. Offering advantages such as reduced intraoperative blood loss, fewer perioperative complications, and faster recovery, MIS is increasingly recommended when feasible, notwithstanding the potential risk of conversion to open surgery. Furthermore, in specialized high-volume centers, MIS currently demonstrates outcomes comparable to or superior to open surgery, even in complex procedures such as post-neoadjuvant sleeve lobectomy and carinal reconstruction. In summary, this review highlights the pivotal role of MIS in managing locally advanced NSCLC and emphasizes the synergy between neoadjuvant therapy and MIS in revolutionizing lung cancer treatment and optimizing patient outcomes.</div></div>","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"5 1","pages":"Article 100115"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145847704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum regarding missing statements in previously published articles","authors":"","doi":"10.1016/j.cson.2026.100116","DOIUrl":"10.1016/j.cson.2026.100116","url":null,"abstract":"","PeriodicalId":100278,"journal":{"name":"Clinical Surgical Oncology","volume":"5 1","pages":"Article 100116"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146038547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}